Reversibility of Tardive Dyskinesia Syndrome

Reversibility of Tardive Dyskinesia Syndrome

In Response To: Zutshi D, Cloud LJ, Factor SA. Dopamine receptor blocking agents: Experience from a university-based movement disorder clinic. Tremor Other Hyperkinet Mov. 2014; 4. doi: 10.7916/D8MS3R8C.

Reversibility and Irreversibility of Tardive Dyskinesia following Neuroleptic Withdrawal

being assessed by means of the Abnormal Involuntary Movement Scale (AIMS). In a preliminary evaluation we analyzed the data from the first 16 patients that completed the study (6 male, IO female, age S1.6* 18.6 years). We found a significant improvement in older patients (age> 40 years) on alpha-tocopherol as compared to the placebo group (p < 0.05). No therapeutic effects of alphatocopherol we...

Metoclopramide and tardive dyskinesia.

Metoclopramide (MCP) is a D-2 receptor blocker (Kebabian and Calne 1979), which has been available by prescription in the United States since 1979 for use as an antiemetic in a wide range of situations. One of the common indications for MCP is the &eatment of diabetic gastroparesis (Physicians' Desk Reference 1993). A few recent reports suggest that diabetes mellitus may be a risk factor for ta...

Sulpiride in tardive dyskinesia.

The abnormal involuntary movements in tardive dyskinesia can be reduced by the dopamine antagonist drugs, phenothiazines and butyrophenones, but most cause an increase in Parkinsonian signs. Sulpiride, a benzamide derivative, and selective antagonist of D2 receptors had a significantly beneficial effect on most of 15 patients (p less than 0.01). In 12 patients the improvement was marked. The re...

Clozapine-induced Tardive Dyskinesia